About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Quality Of Life While Receiving Faslodex | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT00643513

Quality Of Life While Receiving Faslodex

To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.

Lead sponsor: AstraZeneca•24 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Histologic and/or cytological proven breast cancer.
•Patients with metastases of breast cancer ± postmenopausal primary tumor ≥12 months.
•Positive oestrogen receptors (ER+), positive progesterone receptors (PgR+) or unknown hormonal receptors (if duration between surgery and metastasis occurring is not less 2 years) which are indirect confirmation of hormone sensitive tumor.
•ECOG performance status of ≤ 2
•Patient willingness to take part in the programm
•Life expectancy of more than 6 months.
•Patient ability to complete a questionnaire.

Exclusion Criteria

•Contraindications for Faslodex therapy
•Other anticancer therapy (chemotherapy, hormonal therapy with other drugs, radiotherapy), except for radiotherapy of sites which are not only measurable or evaluable manifestation of disease.

Related studies

RECRUITINGPhase 3

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

RECRUITINGPhase 1

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

NCT06347068 · Breast Cancer, Relapse, and more

A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship

NCT07655934 · Breast Cancer

MRg-NIRS Imaging System Breast Cancer Trial

NCT06400563 · Breast Cancer

RECRUITINGPhase 1/2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 22, 2009Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment120

Start dateJun 2007

Last updatedApr 22, 2009

Condition

Locations shown

Research Site

?rasnodar

Research Site

Astrakhan

Research Site

Blagoveshenk

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 22, 2009Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions